Published in Cancer Weekly, November 1st, 2005
The R&D part of the collaboration, which covers the development of five cancer diagnostic tests, has been extended for a minimum of 6 months, with the option to prolong and potentially expand for another 18 months. Financial terms were not disclosed.
"Shortly before announcing final validation data for our two lead products, we extended our R&D partnership. This gives both parties the flexibility to act based upon the final outcomes of these programs. I expect further newsflow from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.